Friberg Sten G, Kahn Lydia Bennedich, Agvald Per, Gustafsson Lars E
Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden.
Eur J Pharmacol. 2006 Oct 10;547(1-3):143-51. doi: 10.1016/j.ejphar.2006.07.006. Epub 2006 Jul 21.
Nitric oxide (NO) is a marker of airway inflammation in humans, despite not having effects on basal bronchial tone. Inhibition of NO synthesis can lead to enhanced airway reactivity in humans and it is therefore of importance to understand how bronchial provocation can affect endogenous NO. Presently, we have studied the role of exhaled nitric oxide in airway reactivity by measuring changes in pulmonary mechanics in response to histamine in anaesthetized guinea pigs. Two groups were challenged i.v. and four groups were challenged by aerosol at different doses. One of the i.v. and one of the aerosol groups received an inhibitor of NO synthesis, N(omega)-nitro-L-arginine methyl ester (L-NAME), to reduce endogenous production of NO before histamine challenge. All animals with intact NO production showed a decrease in exhaled nitric oxide after challenge. There were positive correlations between the peak in exhaled nitric oxide and pulmonary resistance, and between the decrease in exhaled nitric oxide and lung compliance. L-NAME pretreatment increased the reactivity to aerosolized histamine but not to i.v. histamine. We conclude that the different ways of administration elicit different response patterns of exhaled nitric oxide, resistance, and compliance, even when compared at similar insufflation pressure changes. The effects of L-NAME suggest that, although different mechanisms might be responsible for the changes in pulmonary mechanics, inhibition of endogenous NO enhances decrements in pulmonary function when histamine is administered in an aerosol. The close relationship between changes in exhaled nitric oxide and changes in lung compliance and pulmonary resistance merits further studies on the relationship between NO and airway reactivity.
一氧化氮(NO)是人体气道炎症的一个标志物,尽管它对基础支气管张力没有影响。抑制NO合成可导致人体气道反应性增强,因此了解支气管激发如何影响内源性NO非常重要。目前,我们通过测量麻醉豚鼠对组胺反应时肺力学的变化,研究了呼出一氧化氮在气道反应性中的作用。两组通过静脉注射进行激发,四组通过不同剂量的气雾剂进行激发。静脉注射组和气雾剂组中的一组在组胺激发前接受了NO合成抑制剂N(ω)-硝基-L-精氨酸甲酯(L-NAME),以减少内源性NO的产生。所有内源性NO产生正常的动物在激发后呼出一氧化氮均减少。呼出一氧化氮峰值与肺阻力之间以及呼出一氧化氮减少与肺顺应性之间存在正相关。L-NAME预处理增加了对雾化组胺的反应性,但对静脉注射组胺的反应性没有影响。我们得出结论,即使在相似的吹入压力变化下进行比较,不同的给药方式也会引起呼出一氧化氮、阻力和顺应性的不同反应模式。L-NAME的作用表明,尽管肺力学变化可能由不同机制引起,但当以气雾剂形式给予组胺时,抑制内源性NO会增强肺功能的下降。呼出一氧化氮变化与肺顺应性和肺阻力变化之间的密切关系值得进一步研究NO与气道反应性之间的关系。